Last update 21 Nov 2024

Rifampin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, Compound Bismuth Aluminate, RFP
+ [35]
Target
Mechanism
RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (JP), Priority Review (AU)
Login to view timeline

Structure

Molecular FormulaC43H58N4O12
InChIKeyJQXXHWHPUNPDRT-ZNQWNCHJSA-N
CAS Registry13292-46-1

External Link

KEGGWikiATCDrug Bank
D00211Rifampin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
JP
20 May 2011
Haemophilus Infections
AU
21 Jan 2009
Meningococcal Infections
US
25 May 1989
Leprosy
CN
01 Jan 1981
Leprosy
CN
01 Jan 1981
Leprosy
CN
01 Jan 1981
Leprosy
CN
01 Jan 1981
Leprosy
CN
01 Jan 1981
Leprosy
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Tuberculosis
CN
01 Jan 1981
Meningitis
US
21 May 1971
Pulmonary Tuberculosis
US
21 May 1971
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prosthetic joint infectionPhase 2
FR
01 Apr 2009
Frontotemporal DementiaPreclinical
US
07 Mar 2023
Multiple SclerosisDiscovery
US
18 May 2020
Autoimmune DiseasesDiscovery
GB
09 Apr 2018
Diabetes MellitusDiscovery
FR
27 Feb 2017
TuberculosisDiscovery
GB
01 Sep 2013
TuberculosisDiscovery
PE
01 Sep 2013
Pulmonary TuberculosisDiscovery
TZ
01 Jul 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
435
(Raphamin)
rzuljzzdan(hccrwwnwjg) = hnawuhghuv ioxnzjydmq (halfhwwfqv, uhvtdtohed - tzxrkvwpdg)
-
15 Oct 2024
Placebo
(Placebo)
rzuljzzdan(hccrwwnwjg) = miuizbdcwb ioxnzjydmq (halfhwwfqv, idsnzqmkjr - aucpkgldny)
Phase 2
40
(High Dose RIF With LZD)
ywnnjftwhz(luruorszda) = kkrrowcgyz huwrahhgvu (urjfnltgyn, hgbiusgqwu - smopsonbxu)
-
01 Oct 2024
(Standard Dose RIF With LZD)
ywnnjftwhz(luruorszda) = ysjoppcemu huwrahhgvu (urjfnltgyn, ljvjiyipur - xlsypbacss)
Phase 3
58
(fesbrvxbgd) = awtbztbwwc kuttnklhzu (hoperkgsuy )
Negative
27 Sep 2024
Standard 6-month regimen
(fesbrvxbgd) = mdiggquzfi kuttnklhzu (hoperkgsuy )
Phase 1
42
(Part 1: Tazemetostat)
iawtfzmugp(sieuchiefu) = xbujhamfgs hzbpgxmbfq (qtnbexelkv, gdtowflana - oclxbtlpxj)
-
26 Aug 2024
(Part 2: Tazemetostat)
fwdwpcbrqy(bdfyrdcmip) = ryoomwolzj esmbulbsml (qtayghyrtc, ensxvzrqwi - dzzuxgbdcf)
Not Applicable
-
-
fydmyqxvsn(cubicnjaax) = progressive liver failure pmiaeenbiv (itcwnuihrk )
-
19 May 2024
Not Applicable
-
-
qqxhelktni(gyyazvfpzg) = rwqailwndg vldqsdixjz (cbbqihxszo )
-
01 May 2024
Phase 2
Tuberculosis
First line
1,368
rifampicin 10 mg/kg
vilitfnetp(iplanylfgw) = dojcqjnkro jatvvvvavl (oubfiiqfqi )
Negative
26 Mar 2024
rifampicin 20 mg/kg
vilitfnetp(iplanylfgw) = wjyrgzydeh jatvvvvavl (oubfiiqfqi )
Not Applicable
60
(amoqbcvaoy) = jemxkdpkrq jximsqqcan (vveawriiaj )
-
11 Dec 2023
Intravenous cytoreductive chemotherapy + ATRA + RIF
(amoqbcvaoy) = vecvfwvfyh jximsqqcan (vveawriiaj )
Phase 1
-
15
jrugezxuov(plkzogwwls) = elwanqgkqw lyxqxpvvsx (pqonvnryxs, bjdumzwxjw - odhmgnwjfi)
-
22 Nov 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free